BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA
BLA Includes Substantial Body of Data from Pivotal Phase 3 and Ongoing Phase 1/2 Studies
If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A
SAN RAFAEL, Calif., Sept. 29, 2022 /PRNewswire/ -- BioMarin...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Gene Therapy | Genetics | Haemophilia | Hemophilia | New Drug Applications | Study